The Future: How Do We Reach the “Brave New World” of Diverse & Equitable Clinical Trials
Now that we have discussed the definitions, goals and best practices of diverse clinical trials it is time to ask the question: What specific actions can be taken to create truly equitable and diverse clinical trials?
Featuring a panelist from the Center for Medicine in the Public Interest.
Abstract:
In our first three webinars we discussed the definitions, goals and clinical-operational best practices – and organizational change – to enable a more diverse patient base accessing clinical trials. One key remaining question as we look to the future is what specific enforceable and measureable actions can be taken to drive, and mandate, meaningful and equitable change? Despite many efforts over more than a decade, and recent impetus for change – as evidenced in the case studies we’ve discussed in this webinar series – there is still much work to be done. In this final webinar of the series, we explore how – or if – policy innovations, such as government-led mandates and incentives, can move the industry forward as one. Speakers will examine the advantages and disadvantages of implementing penalties for failing to conduct inclusive trials versus rewards for leading the way on this issue. They will discuss examples from outside the biopharma industry that can serve to guide best practices, and identify opportunities for achieving true and lasting change. How can we use these carrots and sticks to overcome social injustice that has become entrenched for generations? How can we work together with leadership in both the public and private sector, with organizations ranging from the Center for Medicare and Medicaid Services to the Bill and Melinda Gates Foundation and beyond, to create truly inclusive trials that deliver real results for all of our communities? Finally, what concrete steps can we take to make clinical trials truly inclusive?
Moderator:
Stephen Keith, MD
- Over 25 years of experience in biopharma industry in vaccines development (e.g. influenza Type B, meningococcal, pneumococcal, and Group B Strep. as well as diphtheria, tetanus, pertussis, and inactivated polio vaccines). Joined Syneos Health in 2018 as medical leader and also serves to support Patient Diversity initiatives.
- Previously, held C-level positions at 3 biotech companies, and was a General Partner in a life sciences venture capital organization.
- Prior to entering the pharmaceutical industry, served as Health Policy Advisor to the U.S. Senate Committee on Labor and Human Resources, under Senator Edward M. Kennedy.
- MD Pediatrician by training /practice, and RW Johnson Clinical Scholar at UCLA with qualifications in Public Health. Faculty member at the Charles Drew Medical School & UCLA School of Medicine (Pediatrics). Fellow of the Academy of Pediatrics, and Diplomate of the American Board of Pediatrics.
- Board of Directors of National Medical Fellowships, and Community Health Charities.
